The immune checkpoint inhibitors treatment of head and neck squamous cell carcinoma: an expert consensus.

Lei Liu; Zhongzheng Xiang; Yi LI; Wei Guo; Kai Yang; Jun Wang; Zhijun Sun; Guoxin Ren; Jianguo Zhang; Moyi Sun; Wei Ran; Guilin Huang; Zhangui Tang; Longjiang LI

Return

The immune checkpoint inhibitors treatment of head and neck squamous cell carcinoma: an expert consensus.

Author: Lei LIU ¹ ; Zhongzheng XIANG ¹ ; Yi LI ² ; Wei GUO ³ ; Kai YANG ⁴ ; Jun WANG ¹ ; Zhijun SUN ⁵ ; Guoxin REN ³ ; Jianguo ZHANG ⁶ ; Moyi SUN ⁷ ; Wei RAN ⁸ ; Guilin HUANG ⁹ ; Zhangui TANG ¹⁰ ; Longjiang LI ²
Author Information

1. Dept. of Head and Neck Oncology, West China Hospital of Sichuan University, Chengdu 610041, China.
2. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Dept. of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
3. Dept. of Oral and Maxillofacial-head and Neck Oncology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai 200011, China.
4. Dept. of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
5. Dept. of Oral and Maxillofacial Surgery, School & Hospital of Stomatology, Wuhan University, Wuhan 430079, China.
6. Dept. of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing 100081, China.
7. Dept. of Oral and Maxillofacial Surgery, Hospital of Stomatology, Air Force Medical University, Xi'an 710032, China.
8. Dept. of Oral and Maxillofacial Surgery, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
9. Dept. of Oral and Maxillofacial Surgery, Stomatological Hospital, Zunyi Medical University, Zunyi 563000, China.
10. Dept. of Oral and Maxillofacial Surgery, Xiangya School of Stomatology, Central South University, Changsha 410000, China.
Publication Type:Journal Article
Keywords: expert consensus; head and neck squamous cell carcinoma; immune checkpoint inhibitors; immunotherapy
MeSH: Humans; Squamous Cell Carcinoma of Head and Neck/drug therapy*; Immune Checkpoint Inhibitors; Consensus; Neoplasm Recurrence, Local/pathology*; Head and Neck Neoplasms/drug therapy*
From: West China Journal of Stomatology 2022;40(6):619-628
CountryChina
Language:English
Abstract: Immune checkpoint inhibitors (ICIs) present significant efficacy in the treatment of malignant tumors, and they have been approved as the first-line of treatment for various cancers. Pembrolizumab monotherapy or combined with chemotherapy has been recommended by domestic and foreign guidelines for the first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma. Although ICIs represent a milestone in the treatment of head and neck squamous cell carcinoma, potential problems still need to be addressed, such as the selection of the efficacy predictors for ICIs, the evaluation of the tumor response to ICIs, and the treatment of immune hyperprogression and immune-related adverse events. Therefore, to form a relatively unified understanding of ICIs treatment for head and neck squamous cell carcinoma, we integrated the clinical experience of multi-disciplinary experts of head and neck cancers on the basis of current clinical hot issues and finally developed this consensus.